[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO974685D0 - Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse - Google Patents

Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse

Info

Publication number
NO974685D0
NO974685D0 NO974685A NO974685A NO974685D0 NO 974685 D0 NO974685 D0 NO 974685D0 NO 974685 A NO974685 A NO 974685A NO 974685 A NO974685 A NO 974685A NO 974685 D0 NO974685 D0 NO 974685D0
Authority
NO
Norway
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
acetamide derivatives
Prior art date
Application number
NO974685A
Other languages
English (en)
Other versions
NO974685L (no
NO310619B1 (no
Inventor
Teruya Murata
Katsuhiko Hino
Makato Oka
Mari Itoh
Kiyoshi Furukawa
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of NO974685D0 publication Critical patent/NO974685D0/no
Publication of NO974685L publication Critical patent/NO974685L/no
Publication of NO310619B1 publication Critical patent/NO310619B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO19974685A 1995-04-13 1997-10-10 Acetamidderivater og farmasöytisk preparat inneholdende disse NO310619B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11393795 1995-04-13
PCT/JP1996/000977 WO1996032383A1 (fr) 1995-04-13 1996-04-10 Derives de l'acetamide, procede de fabrication et composition medicamenteuse a base de ces derives

Publications (3)

Publication Number Publication Date
NO974685D0 true NO974685D0 (no) 1997-10-10
NO974685L NO974685L (no) 1997-12-12
NO310619B1 NO310619B1 (no) 2001-07-30

Family

ID=14624947

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974685A NO310619B1 (no) 1995-04-13 1997-10-10 Acetamidderivater og farmasöytisk preparat inneholdende disse

Country Status (25)

Country Link
US (1) US5972946A (no)
EP (1) EP0826673B1 (no)
KR (1) KR100433589B1 (no)
CN (1) CN1094929C (no)
AR (1) AR002289A1 (no)
AT (1) ATE228113T1 (no)
AU (1) AU694647B2 (no)
BR (1) BR9604894A (no)
CA (1) CA2218033A1 (no)
CZ (1) CZ289093B6 (no)
DE (1) DE69624916T2 (no)
DK (1) DK0826673T3 (no)
ES (1) ES2187644T3 (no)
HU (1) HUP9801688A3 (no)
IL (1) IL117659A (no)
NO (1) NO310619B1 (no)
NZ (1) NZ304982A (no)
PL (1) PL322819A1 (no)
PT (1) PT826673E (no)
RO (1) RO117532B1 (no)
RU (1) RU2160256C2 (no)
SK (1) SK281840B6 (no)
TW (1) TW450963B (no)
WO (1) WO1996032383A1 (no)
ZA (1) ZA962438B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0781766T3 (da) * 1994-09-09 2004-07-26 Nippon Shinyaku Co Ltd Heterocyclisk derivat og medikament
US6333358B1 (en) 1997-08-04 2001-12-25 Taisho Pharmaceutical Co., Ltd. Aryloxyaniline derivatives
WO1999026614A1 (en) 1997-11-21 1999-06-03 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
FR2778564B1 (fr) * 1998-05-13 2001-07-13 Sanofi Sa Utilisation de composes reduisant l'apoptose
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
JP2002241369A (ja) * 1998-05-18 2002-08-28 Dainippon Pharmaceut Co Ltd ４−ピリミジニルアミノアセトアミド誘導体及びそれを含有する医薬組成物
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1140106B1 (en) 1998-12-18 2005-08-03 Scios Inc. Treatment of diseases involving cyst formation
ES2268894T3 (es) 1998-12-18 2007-03-16 Scios Inc. Agonistas y antagonistas de receptores de benzodiazepina de tipo periferico.
EP1607744A3 (en) * 1998-12-18 2009-09-30 Scios Inc. Treatment of diseases involving cyst formation with combinations comprising a PTBR agonist
PL350050A1 (en) 1999-01-22 2002-10-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
EP1144364B1 (en) 1999-01-22 2005-07-13 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
CN1336921A (zh) 1999-01-22 2002-02-20 依兰制药公司 抑制vla－4介导的白细胞粘附的稠合环杂芳基和杂环化合物
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19904710A1 (de) 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
US7037916B2 (en) * 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
KR20020067037A (ko) * 1999-11-17 2002-08-21 다이닛본 세이야꾸 가부시끼가이샤 [5-클로로-6-페닐-2-(4-트리플루오로메틸페닐)-4-피리미디닐아미노]아세트아미드 유도체, 그의 제조방법, 그를함유하는 제약 조성물, 및 이들 화합물의 중간체
MXPA01011743A (es) * 2000-03-16 2003-09-05 Neurogen Corp Arilpirimidinas substituidas 5-.
WO2002006242A2 (en) * 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR20030030005A (ko) * 2000-09-15 2003-04-16 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
ZA200301703B (en) * 2000-09-15 2004-03-02 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
EP1698627A1 (en) * 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN100340555C (zh) * 2000-12-21 2007-10-03 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
WO2003049739A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
EP1472245A2 (en) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
WO2003072107A1 (en) * 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Substituted pyrimidinones and pyrimidinthiones
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003257078B2 (en) 2002-08-02 2010-04-01 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of GSK-3
PL377847A1 (pl) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
PE20050355A1 (es) * 2003-08-05 2005-05-16 Vertex Pharma Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
CN1902193B (zh) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
KR20060129023A (ko) * 2004-02-23 2006-12-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 헤테로환 화합물
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
CA2619517A1 (en) * 2005-08-18 2007-02-22 Michael Mortimore Pyrazine kinase inhibitors
EP1940827B1 (en) 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
EP1940826B1 (en) * 2005-09-29 2010-12-29 Elan Pharmaceuticals Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
US7820685B2 (en) * 2005-11-03 2010-10-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20070112012A1 (en) * 2005-11-11 2007-05-17 Markus Boehringer Carbocyclic fused cyclic amines
EP1996559A1 (en) 2006-02-27 2008-12-03 Elan Pharmaceuticals Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
JP5249919B2 (ja) * 2006-03-29 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピリジン及びピリミジン誘導体
WO2008057940A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
ATE474835T1 (de) * 2006-12-19 2010-08-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EP1941879A1 (en) * 2007-01-05 2008-07-09 PAION Deutschland GmbH Neuroprotective agent for the treatment of neuronal damage
WO2008112642A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
AU2008226461A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
AU2008226466B2 (en) * 2007-03-09 2013-06-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2681516A1 (en) * 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of janus kinases
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101679387A (zh) * 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
MX2009011812A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
EP2152694A2 (en) 2007-05-02 2010-02-17 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
JP2010528021A (ja) * 2007-05-24 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
NZ582879A (en) * 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP4800445B2 (ja) 2008-06-19 2011-10-26 武田薬品工業株式会社 複素環化合物およびその用途
CN102215816A (zh) * 2008-09-03 2011-10-12 沃泰克斯药物股份有限公司 共晶和包含所述共晶的药物制剂
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
SG10201401836RA (en) 2009-04-27 2014-10-30 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
BR112013011737A2 (pt) 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
KR102595163B1 (ko) 2015-01-06 2023-10-30 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
KR20230160955A (ko) 2015-06-22 2023-11-24 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631045A (en) * 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
US3631036A (en) * 1969-11-04 1971-12-28 American Home Prod 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds
FR2263750A1 (en) * 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
FR2525595A1 (fr) * 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
JPH07165721A (ja) * 1993-12-15 1995-06-27 Sumitomo Chem Co Ltd 放射性イソキノリンカルボキサミド誘導体

Also Published As

Publication number Publication date
AR002289A1 (es) 1998-03-11
KR19980703815A (ko) 1998-12-05
ZA962438B (en) 1996-10-01
EP0826673A1 (en) 1998-03-04
ATE228113T1 (de) 2002-12-15
KR100433589B1 (ko) 2004-09-13
WO1996032383A1 (fr) 1996-10-17
CZ289093B6 (cs) 2001-10-17
CN1094929C (zh) 2002-11-27
TW450963B (en) 2001-08-21
AU694647B2 (en) 1998-07-23
CN1186487A (zh) 1998-07-01
DE69624916T2 (de) 2003-04-24
US5972946A (en) 1999-10-26
EP0826673B1 (en) 2002-11-20
NO974685L (no) 1997-12-12
HUP9801688A2 (hu) 1999-03-29
RU2160256C2 (ru) 2000-12-10
SK137497A3 (en) 1998-05-06
PT826673E (pt) 2003-02-28
SK281840B6 (sk) 2001-08-06
NZ304982A (en) 1999-03-29
HUP9801688A3 (en) 2001-11-28
RO117532B1 (ro) 2002-04-30
PL322819A1 (en) 1998-02-16
IL117659A (en) 2000-12-06
ES2187644T3 (es) 2003-06-16
DE69624916D1 (de) 2003-01-02
CZ322397A3 (cs) 1998-02-18
BR9604894A (pt) 1998-07-14
DK0826673T3 (da) 2003-03-24
CA2218033A1 (en) 1996-10-17
IL117659A0 (en) 1996-07-23
EP0826673A4 (en) 1998-09-02
AU5287496A (en) 1996-10-30
NO310619B1 (no) 2001-07-30

Similar Documents

Publication Publication Date Title
NO974685L (no) Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse
NO975987D0 (no) 4-Fenylaminotiazol-derivater, fremgangsmåte for fremstilling av disse og farmasöytiske blandinger inneholdende nevnte derivater
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
DK1156049T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO307827B1 (no) Benzoksazol- og pyridinderivater, anvendelse av dem og farmasøytisk preparat inneholdende dem
NO981817D0 (no) Indolin-2-on-derivater, fremgangsmÕte for fremstilling av dem og farmas÷ytiske blandinger inneholdende dem
NO961006L (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
DK0885204T3 (da) Nye arylglycinamidderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse forbindelser
GB9520584D0 (en) Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
HUP9602635A2 (en) 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
NO950537L (no) Polysubstituerte 3-acylamino-5-fenyl-1,4-benzodiazepin-2-on-derivater, fremgangsmåter for fremstilling derav og farmasöytiske blandinger inneholdende dem
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
NO961000D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
HUP9901485A2 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
DK0735042T3 (da) Maltitolsammensætning og fremgangsmåde til fremstilling deraf
IL117495A0 (en) Beta-alanine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
NO975076D0 (no) Farmasöytisk preparat som inneholder tiagabinhydroklorid, og fremgangsmåte for dets fremstilling
FI960316A0 (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
NO955320D0 (no) Substituerte 4-fenyltiazolderivater, fremgangsmåte for fremstilling derav og farmasöytiske blandinger som inneholder dem
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
NO970136D0 (no) Granulös formulering inneholder mikroorganismer, fremgangsmåte for fremstilling og anvendelse derav
DK0806949T3 (da) Ny farmaceutisk komposition, der indeholder trimebutin, og fremgangsmåde til fremstilling deraf
DK1100775T3 (da) 2,5-Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til fremstilling deraf, anvendelse deraf og farmaceutiske præparater indeholdende disse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN OCTOBER 2003